Balchem Corporation reported a notable increase in its financial performance for the third quarter and the first nine months of 2025, as detailed in its latest 10-Q filing. For the three months ended September 30, 2025, the company achieved net sales of $267.6 million, an increase of 11.5% from $239.9 million in the same period of 2024. The gross margin also rose to $95.5 million, reflecting an 11.8% increase compared to $85.4 million in the prior year. Net earnings for the quarter reached $40.3 million, or $1.25 per share, up from $33.8 million, or $1.05 per share, in the previous year, marking a 19.1% increase in profitability.
In the nine-month period ending September 30, 2025, Balchem reported net sales of $773.5 million, an 8.4% increase from $713.7 million in the same period of 2024. The gross margin for this period was $276.7 million, up 10.8% from $249.9 million. Net earnings for the nine months were $115.6 million, or $3.57 per share, compared to $94.9 million, or $2.94 per share, in the prior year, representing a 21.8% increase in net income.
The company attributed its growth to strong performance across its three reportable segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment saw a 14.3% increase in sales, driven by higher demand in both nutrients and food ingredients. The Animal Nutrition & Health segment reported a 6.6% increase, while the Specialty Products segment grew by 7.5%. The overall increase in sales was supported by favorable pricing and a positive mix of products, although some segments experienced slight declines in volume.
Operationally, Balchem's total assets increased to $1.66 billion as of September 30, 2025, up from $1.58 billion at the end of 2024. The company also reported a significant reduction in current liabilities, which fell to $126.4 million from $157.7 million, contributing to a stronger balance sheet. The employee headcount stood at approximately 1,355, reflecting the company's ongoing efforts to attract and retain skilled talent in a competitive labor market.
Looking ahead, Balchem remains focused on strategic growth initiatives, including potential acquisitions and investments in its production capabilities. The company is also navigating challenges such as supply chain disruptions and fluctuating market conditions. Balchem's management expressed confidence in its ability to sustain growth and enhance shareholder value through continued innovation and operational efficiency.
About BALCHEM CORP
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments. Its offerings include human-grade choline nutrients, mineral amino acid chelates, MSM, vitamin K2, microencapsulated animal nutrition products, and performance gases like ethylene oxide for medical sterilization. Serving global food, pharmaceutical, animal health, and industrial markets, Balchem leverages proprietary technologies and scientific expertise to deliver high-quality, value-added solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.